GlassScriptPhysician profile
Tanveer Aslam
NPI 1043239965
$8,747.86
in general payments reported to CMS, 2019-2025
44 companies · $1,257 in 2025
The $1,257 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,266 · 2020: $1,485 · 2021: $1,695 · 2022: $1,263 · 2023: $929 · 2024: $854 · 2025: $1,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,038.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $931.42 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Mylan Specialty L.P. | $725.90 | 2019-2024 | Yupelri |
| Amgen INC. | $604.10 | 2019-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $594.96 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Sunovion Pharmaceuticals INC. | $570.12 | 2019-2022 | |
| Abbvie INC. | $535.17 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $472.84 | 2019-2023 | Verquvo, Belsomra, Lagevrio |
| Novo Nordisk INC | $467.58 | 2021-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $413.43 | 2021-2025 | |
| Lilly USA, LLC | $308.10 | 2020-2024 | Mounjaro, Jardiance |
| Teva Pharmaceuticals USA, INC. | $303.25 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $276.92 | 2019-2025 | Rexulti |
| Astellas Pharma US INC | $227.13 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.81 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $214.37 | 2021-2023 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanveer Aslam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.